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Validation Study of the Proposed IASLC Staging Revisions
of the T4 and M Non-small Cell Lung Cancer
Descriptors Using Data from 23,583 Patients in the
California Cancer Registry
Sai-Hong Ignatius Ou, MD, PhD,*†‡ and Jason A. Zell, DO, MPH*†‡
Background: We performed a validation study of the proposed
International Association for the Study of Lung Cancer (IASLC)
tumor, node, metastasis (TNM) and stage grouping revisions on
advanced nonbronchioloalveolar carcinoma (non-BAC) non-small
cell lung cancer (NSCLC).
Methods: Twenty-three thousand five hundred eighty-three patients
from the California Cancer Registry between 1999 and 2003 with
histologically confirmed non-BAC NSCLC and complete TNM
staging were identified and reclassified according to the IASLC
proposed TNM revisions and new stage groupings. Twelve thousand
nine hundred one stage IIIB and IV patients formed the primary
analysis of the changes to T4 and M descriptors. Surveillance,
Epidemiology, and End Results extent of disease codes were used to
identify various T4 and M descriptors. Cox proportional hazards
regression was used to calculate hazard ratios (HRs) among the
stage groupings of the current and proposed staging system with
adjustment for ethnicity, gender, age, histology, histologic grade,
socioeconomic status, surgery, radiation, and chemotherapy.
Results: The proposed changes to the T4 and M descriptors were
supported by overall survival analysis. T4 due to additional nodules
had significant survival advantage over other T4 and M descriptors
among non-BAC NSCLC and individual histology and warrants
down-staging to T3. Pericardial effusion had survival similar to M1b
patients. Cox proportional hazards regression analysis supports sub-
dividing M descriptor into M1a (versus IASLC stage IA; HR 
4.90; 95% confidence interval: 4.49–5.34) and M1b (versus IASLC
stage IA; HR  6.84; 95% confidence interval: 6.30–7.44).
Conclusions: IASLC has greatly improved the T4 and M descrip-
tors allowing better prognostication of advanced non-BAC NSCLC.
Pericardial effusion may be considered as M1b rather than M1a.
Key Words: IASLC lung cancer staging system, AJCC/UICC
staging system, T4 descriptor, M descriptor, Non-small cell lung
cancer, Survival, Pericardial effusion, California Cancer Registry.
(J Thorac Oncol. 2008;3: 216–227)
The current 6th edition of the Union InternationaleContre le Cancer (UICC6) staging system1 for lung
cancer has not been changed since the publication of the
5th edition in 1997.2 Nevertheless, formal processes for
continuous improvement of the tumor, node, metastasis
(TNM) classification has been established since 2002.3 A
new proposed revision of the tumor (T),4 nodes (N),5 and
metastasis (M)6 descriptors for the forthcoming (7th edi-
tion) UICC lung cancer staging system has been recently
proposed by the International Association for the Study of
Lung Cancer (IASLC) after a rigorous study by an inter-
national panel using data from Europe, Asia, Australia, and
North America. The proposed revision maintained the
current N descriptors in the non-small cell lung cancer
(NSCLC) staging system5 but proposed several changes to
the T descriptor.4 For early stage T descriptor, one major
revision was to subdivide T1 into T1a (2 cm) and T1b
(2 cm to 3 cm) and subdivide T2 into T2a (3 cm to 5
cm), T2b (5 cm to 7 cm), and T3 (7 cm). For advanced
T descriptors, one major revision is to reclassify T4 due to
additional satellite nodules in the same lobe to T3 while
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upstaging pleural dissemination (malignant pleural effu-
sion/pleural nodules) and malignant pericardial effusion to
M1a.4 The major revision to the M descriptor is to subdi-
vide it into M1a and M1b. “Contralateral intrapulmonary
nodules” is grouped together with “malignant pleural dis-
semination” and “malignant pericardial effusion” into the
new M1a category. All other distant metastasis will be
grouped as M1b.6 One of the proposed stage grouping
changes is reclassifying the new T4N0-1M0 from stage
IIIB as stage IIIA.7 All these revisions and new grouping
were internally validated and the Surveillance, Epidemiol-
ogy, and End Results (SEER) database from 1998 to 2000
was used for external validation.8
We have previously shown that patients with T4 dis-
ease due to additional nodules in the same lobe and patients
with M disease due to ipsilateral intrapulmonary nodules had
better survival than T4 and M by other criteria respectively
for both bronchioloalveolar carcinoma (BAC) and non-BAC
NSCLC using SEER database.9,10 We are thus interested in
performing an external validation study of the IASLC pro-
posed staging changes using the California Cancer Registry
(CCR) database. Using CCR database we have previously
published that patients with BAC had statistically improved
survival after the publication of the World Health Organiza-
tion (WHO) changes in the definition of BAC.11 BAC also
has unique clinicopathologic (more female, more nonsmok-
ers, higher incidence of additional nodules in the same lobe,
higher incidence of intrapulmonary metastasis) and molecular
features (higher percentage of epidermal growth factor recep-
tor mutations).11–13 As such we have performed a separate
validation study on these staging changes specifically to BAC
using CCR.14
In this study, we adopted all the IASLC proposed
changes to the T and M descriptors and reclassified all
non-BAC NSCLC patients according to the new stage
grouping and primarily analyzed survival differences due
to the changes to the T4 and M descriptors. The 1999
WHO change in the definition of BAC15 has changed the
proportion and clinicopathologic features of BAC and
adenocarcinoma11,12 and may have been affected survival
of other NSCLC histologies. Thus we analyzed patients
diagnosed after 1998 (1999–2003) similar to how IASLC
used the SEER database from 1998–2000 as the external
validation set.6
PATIENTS AND METHODS
Objective
The primary outcome measure was to compare the
stage-specific overall survival (OS) of advanced non-BAC
NSCLC using current UICC6 staging system and the pro-
posed IASLC staging modifications.
Population
A case-only analysis was conducted on incident
NSCLC patients from CCR diagnosed between 1999 and
2003 who had complete TNM staging data and follow-up
data. We limited the analysis to patients diagnosed after
1999, i.e., date of the WHO revised classification of lung
tumors.15 Data were abstracted from medical and labora-
tory records by trained tumor registrars according to Can-
cer Reporting in California: Vol. IV, Abstracting and
Coding Procedures for Hospitals.16
Tumor site and histology were abstracted as previ-
ously described.9–11 BAC histology was excluded, as we
have separately performed a validation study for this
histologic subtype.14 Non-small cell histologies were cat-
egorized as undifferentiated NSCLC if they were not
coded as adenocarcinoma, squamous cell carcinoma, large
cell carcinoma, or as a metastatic lung lesion from a
separate primary tumor, as previously described.9–11 Cy-
tology specimens have been shown to be inaccurate in
NSCLC diagnosis compared with histology specimens.17
Thus, in an attempt to limit potential variability in histo-
logic classification, only histologically confirmed NSCLC
cases were analyzed. Patient demographic data were ab-
stracted using SEER codes. The measurement of socioeco-
nomic status used in this analysis was a composite measure
using CCR and census data as previously described.18,19
Radiation therapy and surgical techniques were abstracted
using SEER codes. Chemotherapy given during the first
course of therapy was ascertained using CCR codes.
For each patient in CCR, the Extent of Disease
(EOD) coding variable was analyzed, to allow recoding
into and comparison of the existing versus proposed re-
vised staging system. EOD 65 which codes for “separate
tumor nodule(s) in the same lobe,” EOD 71 which codes
for “heart, visceral pericardium,” EOD 72 which codes for
“malignant pleural effusions,” EOD 73 which codes for
“adjacent rib,” EOD 75 which codes for “sternum, verte-
bra(e) skeletal muscle, skin of chest,” EOD 77 which codes
“separate tumor nodule(s) in separate lobe,” EOD 78
which codes for “separate tumor nodule(s) in contralateral
lung” and EOD 79 which codes for “(malignant) pericar-
dial effusion” were used to identify the various T and M
descriptors that were reclassified by IASLC. A total of 226
T3 patients with EOD 73 were reclassified as T4 according
to the UICC6 staging system.
Restaging Patients According to the IASLC
Revision for T4 and M Descriptors
Based on proposed IASLC revisions and stage group-
ing, the T4 descriptor for additional tumor nodules in the
same lobe was changed to T3. We restaged these patients
(T3N0M0) as stage IIB, patients with T3N1–2M0 as IIIA,
and patients with T3N3M0 remained staged IIIB. The T4
descriptor for pleural dissemination (malignant pleural effu-
sion/pleural nodules) was changed to M1a and so were
patients with malignant pericardial effusion and we restaged
these patients as stage IVA. The M descriptor for ipsilateral
intrapulmonary nodules was changed to T4. These patients
were staged according to the nodal status. Patients with
contralateral intrapulmonary nodules were staged as M1a and
grouped as stage IVA. Even though the proposed IASLC
staging does not officially separate stage IV into stage IVA
and stage IVB, we grouped stage IV patients into two groups
according to M1a and M1b to facilitate Cox proportional
regression analysis. We restaged all T4N0-1M0 patients as
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stage IIIA (which represents a major change in the current
proposed IASLC stage grouping).7
All early stage tumors were also reclassified according
to their tumor sizes and EOD codes and their stage grouping
according to the UICC6 and IASLC proposed changes for the
Cox proportional regression analysis.
Statistical Analyses
Comparisons of demographic, clinical, and patho-
logic variables were made for NSCLC patients, using
Pearson 2 statistic or Fisher exact test for nominal vari-
ables and Student t test for continuous variables. Analysis
of variance with Tukey’s posthoc test was used for multi-
TABLE 1. Clinicopathologic Features of non-BAC NSCLC Patients (N  13,401) with UICC6 T4 and M Descriptors that
Undergo Revisions as Proposed by IASLC
UICC6 Stage IIIB UICC6 Stage IV
T4-“Additional
Nodules”
(%)
T4-“Pleural
Dissemination”
(%)
T4-“Pericardial
Effusion”
(%)
T4-“Invasion”
(%)
M-“Ipsilateral
Pulmonary
Nodules” (%)
M-“Contralateal
Pulmonary
Nodules” (%)
M- “Distant
Metastasis”
(%)
N 422 1773 320 1607 745 1148 6886
Mean age of diagnosis 67.9 69.6 66.1 66.0 67.4 68.6 65.1
(SD) 10.3 11.5 12.3 11.0 10.4 11.3 11.3
Gender
Male 228 (54.0) 1033 (58.2) 168 (52.5) 952 (59.2) 404 (54.2) 627 (54.6) 3975 (57.7)
Female 194 (46.0) 740 (41.7) 152 (45.7) 655 (40.8) 341 (45.8) 521 (45.4) 2911 (42.3)
Race
Caucasian 336 (79.6) 1243 (70.1) 231 (72.2) 1153 (71.8) 537 (72.1) 819 (71.3) 4888 (71.0)
African-American 31 (7.4) 146 (8.2) 22 (6.9) 159 (9.9) 67 (9.0) 84 (7.3) 630 (9.2)
Hispanic 26 (6.2) 206 (11.6) 36 (11.3) 138 (8.6) 77 (10.3) 120 (10.5) 703 (10.2)
Chinese 5 (1.2) 50 (2.8) 5 (1.6) 32 (2.0) 12 (1.6) 31 (2.7) 187 (2.7)
Non-Chinese Asian 23 (5.5) 123 (6.9) 23 (7.2) 120 (7.5) 51 (6.9) 89 (7.6) 451 (6.6)
Other 1 (0.2) 5 (0.3) 3 (0.9) 5 (0.3) 1 (0.1) 5 (0.4) 27 (0.4)
Socioeconomic status (SES)
Quintile 1 (SES1-lowest) 58 (13.7) 339 (19.1) 58 (18.1) 242 (15.1) 120 (16.1) 177 (15.4) 1074 (15.6)
Quintile 2 (SES2) 83 (19.7) 383 (21.6) 65 (20.3) 318 (19.8) 138 (18.5) 245 (21.3) 1327 (19.3)
Quintile 3 (SES3) 98 (23.2) 390 (22.0) 82 (25.6) 378 (23.5) 173 (23.2) 254 (22.1) 1505 (21.9)
Quintile 4 (SES4) 92 (21.8) 360 (20.3) 59 (18.4) 345 (21.5) 156 (20.9) 241 (21.0) 1542 (22.4)
Quintile 5 (SES5-highest) 91 (21.6) 301 (17.0) 56 (17.5) 324 (20.2) 158 (21.2) 231 (20.1) 1438 (20.9)
Histology
Adenocarcinoma 211 (50.0) 692 (39.0) 128 (40.0) 528 (32.9) 359 (48.2) 487 (42.4) 3173 (46.1)
Squamous cell carcinoma 97 (23.0) 503 (28.4) 85 (26.6) 571 (35.5) 196 (26.3) 290 (25.3) 1092 (15.9)
Large Cell carcinoma 19 (4.5) 111 (6.3) 25 (7.8) 74 (4.6) 28 (3.8) 64 (5.6) 440 (6.4)
Undifferentiated carcinoma 95 (22.5) 467 (26.3) 82 (25.6) 434 (27.0) 162 (21.7) 307 (26.7) 2181 (31.7)
Histologic grade
Well-differentiated 29 (6.9) 49 (2.8) 11 (3.4) 37 (2.3) 37 (5.0) 48 (4.2) 115 (1.7)
Moderately-differentiated 92 (21.8) 254 (14.3) 32 (10.0) 264 (16.4) 146 (19.6) 184 (16.0) 726 (10.5)
Poorly-differentiated 197 (46.7) 733 (41.3) 128 (40.0) 715 (44.5) 297 (39.9) 405 (35.3) 2436 (35.4)
Un-differentiated 13 (3.1) 83 (4.7) 21 (6.6) 68 (4.2) 30 (4.0) 44 (3.8) 321 (4.7)
Unknown 91 (21.6) 654 (36.9) 128 (40.0) 523 (32.5) 235 (31.5) 467 (40.7) 3288 (47.7)
Surgery
Yes 245 (58.1) 124 (7.0) 13 (4.1) 366 (22.8) 231 (31.0) 89 (7.8) 395 (5.7)
No 177 (41.9) 1649 (93.0) 307 (95.9) 1241 (77.2) 514 (69.0) 1059 (92.2) 6487 (94.2)
Unknown 0 (0.0) 0. (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 4 (0.1)
Radiation
Yes 159 (37.7) 660 (37.2) 122 (38.1) 1081 (67.3) 266 (35.7) 334 (29.1) 3852 (55.9)
No 263 (62.3) 1113 (62.8) 198 (61.9) 526 (32.7) 479 (64.3) 814 (70.9) 3034 (44.1)
Chemotherapy
Yes 155 (36.7) 711 (40.1) 155 (48.4) 960 (59.7) 336 (45.1) 549 (47.8) 3141 (45.6)
No 261 (61.8) 999 (56.3) 154 (48.1) 600 (37.3) 387 (51.9) 562 (49.0) 3524 (51.2)
Unknown 6 (1.4) 63 (3.6) 11 (3.4) 47 (2.9) 22 (3.0) 36 (3.1) 221 (3.2)
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ple comparisons of continuous variables. Univariate survival
rate analyses were estimated using the Kaplan and Meier
method, with comparisons made between groups by the log-rank
test. Cox proportional hazards modeling using time since diag-
nosis were performed. Each variable in the model was coded
using dummy variables. All statistical analyses were con-
ducted using SAS 9.1 statistical software (SAS Institute,
Inc., Cary, NC). Statistical significance was assumed for a
two-tailed p value less than 0.05.
Ethical Considerations
This research study was approved by the University of
California Irvine Institutional Review Board (IRB #2004–
3971).
RESULTS
Patients and Tumor Characteristics
About 43,655 incident cases of NSCLC were identified
between 1999 and 2003 in CCR, including 2010 BAC pa-
tients that were separately analyzed and reported elsewhere.14
Of the remaining 41,645 non-BAC NSCLC patients, 30,711
(74%) had a histologically confirmed diagnosis. An addi-
tional 196 cases where no EOD were available, 997 cases
where tumor status were unknown (TXM0), and 5935 cases
where nodal status were unknown (NXM0) were excluded. A
total of 23,583 patients comprised the final study population
for this report used to generate the comparison of the hazard
ratio (HR) of the UICC6 and IASLC stages by Cox proportional
hazards regression analysis. There were a total of 4122 (17.5%)
stage IIIB patients and 8779 (37.2%) stage IV patients. These
12,901 patients comprised the basis for the primary T4 and M
descriptor analysis in this report. The median follow-up time for
the advanced stage IIIB/IV patients was 9 months (0 to 60
months). Among these IIIB/IV patients, adenocarcinoma (43.2%)
was the most frequent tumor histology followed by undiffer-
entiated histology (28.9%), squamous cell carcinoma (22.0%)
and large cell carcinoma (5.9%).
Among UICC6 advanced stage IIIB patients, 10.2%
had additional nodules in the same lobe, 43.0% had malignant
pleural effusion, 7.8% had malignant pericardial effusion,
39.0% were other “T4 invasion.” Among UICC6 stage IV
patients, 13.1% had ipsilateral intrapulmonary nodules, 8.5%
with contralateral pulmonary intrapulmonary nodules, and
78.4% had distant metastasis. The clinicopathologic character-
istics of the seven nonoverlapping T4 and M categories were listed
in Table 1.
Both “T4-additional nodules” (50.0%) and “ipsilat-
eral intrapulmonary nodules” (48.2%) categories had the
highest proportional of adenocarcinoma. Of note, signifi-
cantly more patients with additional nodules in the same
lobe (58.1%) and ipsilateral intrapulmonary nodules
(31.0%) underwent surgical than the other five categories.
The proportional of patients with unknown histologic
grade increased with more advanced disease. Nevertheless,
these patients were included in subsequent Cox propor-
tional hazards regression analyses.
External Validation of Univariate Survival
Analysis
OS of the Seven Subtypes of UICC6 T4 and
M Descriptors that were Reclassified by IASLC
Proposed Staging Changes
The 1-year and 5-year survival estimates and median
OS of T4 patients due to additional nodules in the same lobe,
T4 patients due to malignant pleural dissemination, T4 pa-
FIGURE 1. Overall survival curves of the 7 subtypes of
UICC6 T4 and M descriptors that are reclassified by the pro-
posed IASLC lung cancer staging project.
TABLE 2. Survival Characteristics of non-BAC NSCLC Patients with the Seven Subtypes of UICC6 T4 and M Descriptors that
Undergo Revisions as Proposed by IASLC
UICC6 T4 and M Descriptors (IASLC proposed changes) Total Deaths
1-yr Survival
Estimate (%)
5-yr Survival
Estimate (%)
Median Overall
Survival (mo)
T4-“additional nodules” (IASLC 3 T3) 422 250 64.0 22.6 20
T4-“invasion” (IASLC 3 T4 no change) 1607 1178 47.4 11.5 12
M-“ipsilateral intra-pulmonary nodules” (IASLC 3 T4) 745 555 46.2 9.5 11
M-“contralateral intra-pulmonary nodules” (IASLC 3 M1a) 1148 949 31.1 4.3 7
T4-“pleural dissemination” (IASLC 3 M1a) 1773 1557 22.7 3.9 5
T4-“pericardial effusion” (IASLC 3 M1a) 320 282 17.7 3.4 3
M-“distant metastasis” (IASLC 3 M1b) 6886 6252 18.3 1.3 4
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tients due to malignant pericardial effusion, patients with T4
invasion (IASLC T4), M patients due to ipsilateral intrapul-
monary nodules, M patients due to contralateral intrapulmo-
nary nodules, and M patients due to distant metastasis are
listed in Table 2. The Kaplan-Mierer survival curves of the
seven T4 and M categories are plotted in Figure 1. Identical
survival analyses were performed in each of the four histol-
ogies: adenocarcinoma, squamous cell carcinoma, large cell
carcinoma, and undifferentiated carcinoma. The 1-year and
5-year survival estimates and median OS of the seven sub-
types of T4 and M descriptor categories stratified by histolo-
gies were listed in Table 3. Patients with T4-additional nodules
in the same lobe had significantly better survival as a whole and
within each histology. On the other hand, patients with malig-
nant pleural dissemination or pericardial effusions had dismal
survival.
The survival characteristics (1-year and median OS) of
the CCR validation set was compared with the SEER valida-
tion set used by IASLC for their external validation exercise
and is shown in Table 4. The survival characteristics between
the two database sets were very similar and this provides
validity to our analysis. Malignant pericardial effusion was
not analyzed separately as a category in the IASLC validation
set and thus was not shown in Table 4.
OS of Patients with the New IASLC T4 Descriptor,
UICC6 T4 (Malignant Pleural Dissemination)
Descriptor and UICC6 T4 (Malignant Pericardial
Effusion) Descriptor and without Distant Metastasis
(M0) According to Nodal Statuses
The 1-year and 5-year survival estimates and median
OS of the new IASLC T4 descriptor, UICC6 T4-pleural
TABLE 3. Survival Characteristics of non-BAC NSCLC Patients with UICC6 T4 and M Descriptors that Undergo Revisions as
Proposed by IASLC Stratified by Individual Histology
UICC6 T4 and M Descriptors (IASLC proposed changes) Total Deaths
1-yr Survival
Estimate (%)
5-yr Survival
Estimate (%)
Median OS
(mo)
Adenocarcinoma (N  5578)
T4-“additional nodules” (IASLC 3 T3) 211 117 70.0 25.4 22
T4-“invasion” (IASLC 3 T4 no change) 528 370 51.6 12.3 13
M-“ipsilateral intra-pulmonary nodules” (IASLC 3 T4) 359 254 54.3 12.6 15
M-“contralateral intra-pulmonary nodules” (IASLC 3 M1a) 487 390 35.6 6.3 8
T4-“pleural dissemination” (IASLC 3 M1a) 692 592 24.5 5.0 5
T4-“pericardial effusion” (IASLC 3 M1a) 128 116 14.4 3.0 3
M-“distant metastasis” (IASLC 3 M1b) 3173 2829 22.2 1.4 5
Squamous cell carcinoma (N  2834)
T4-“additional nodules” (IASLC 3 T3) 97 57 60.0 16.1 17
T4-“invasion” (IASLC 3 T4 no change) 571 432 45.8 9.7 11
M-“ipsilateral intra-pulmonary nodules” (IASLC 3 T4) 196 156 37.0 6.8 8
M-“contralateral intra-pulmonary nodules” (IASLC 3 M1a) 290 250 27.6 4.5 7
T4-“pleural dissemination” (IASLC 3 M1a) 503 435 24.3 3.6 5
T4-“pericardial effusion” (IASLC 3 M1a) 85 77 15.8 —a 4
M-“distant metastasis” (IASLC 3 M1b) 1092 1024 14.7 1.8 4
Large cell carcinoma (N  761)
T4-“additional nodules” (IASLC 3 T3) 19 15 55.7 16.7 12
T4-“invasion” (IASLC 3 T4 no change) 74 60 42.8 9.3 9
M-“ipsilateral intra-pulmonary nodules” (IASLC 3 T4) 28 19 33.8 16.9 7.5
M-“contralateral intra-pulmonary nodules” (IASLC 3 M1a) 64 57 28.2 2.4 7
T4-“pleural dissemination” (IASLC 3 M1a) 111 105 14.5 3.1 3
T4-“pericardial effusion” (IASLC 3 M1a) 25 20 22.3 —a 5
M-“distant metastasis” (IASLC 3 M1b) 440 414 10.6 1.3 3
Undifferentiated carcinoma (N  3728)
T4-“additional nodules” (IASLC 3 T3) 95 61 58.6 15.2 16
T4-“invasion” (IASLC 3 T4 no change) 434 316 45.0 15.3 11
M-“ipsilateral intra-pulmonary nodules” (IASLC 3 T4) 162 126 40.7 5.7 10
M-“contralateral intra-pulmonary nodules” (IASLC 3 M1a) 307 252 28.1 2.4 7
T4-“pleural dissemination” (IASLC 3 M1a) 467 425 20.4 2.6 4
T4-“pericardial effusion” (IASLC 3 M1a) 82 69 24.3 —b 3.5
M-“distant metastasis” (IASLC 3 M1b) 2181 1985 16.2 1.0 4
a Data suppressed due to no events after 24 mo.
b Data suppressed due to no events after 24 mo.
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dissemination descriptor and UICC6-pericardial effusion
descriptors were analyzed and listed in Table 5 and plotted
in Figures 2A–C, respectively. Although there were statis-
tically significant survival differences among patients with
malignant pleural dissemination or pericardial effusion
according to the nodal status, the overall dismal survival of
these patients justified reclassifying these patients to a M
descriptor independent of nodal status (Figures 2B, C).
There were also statistically significant survival differ-
ences among patients with T4 invasion according to nodal
status and the differences in survival (1-year survival
estimate difference of approximately 10% and 5 months
improvement in median OS) are large enough to justify
reclassifying patients with T4N0-1 from the traditional
stage IIIB to stage IIIA. Nevertheless, most of these
T4N0-1M0 patients may still not be considered as “resect-
able” as traditionally considered for IIIA disease.
OS Comparison of Patients with Pericardial
Effusion versus Patients with Other M1a
Descriptors (Contralateral Intrapulmonary
Nodules or Malignant Pleural Dissemination) and
M1b Patients
We observed from Tables 2 and 3 that patients with
pericardial effusion had dismal survival similar to the IASLC
M1b category. The HR of survival of patients with pericardial
effusion was compared in a pairwise fashion with other M1a
and M1b descriptors and shown in Table 6. Patients with
pericardial effusion had statistically significant increased risk
of death when compared with other M1a descriptors (con-
tralateral intrapulmonary nodules or malignant pleural dis-
semination). The HR of patients with pericardial effusion was
not statistically significant different from patients with distant
metastasis (M1b). Thus, patients with pericardial effusion
may be considered as M1b especially if an official subdivi-
TABLE 4. Comparison of Survival Characteristics of the CCR Validation Dataset versus the IASLC SEER Validation Set
CCR Validation Set IASLC SEER Validation Set
1-yr Survival
Estimate (%)
Median Overall
Survival (mo)
1-yr Survival
Estimate (%)
Median Overall
Survival (mo)
T4-“additional nodule in same lobe” (IASLC T3) 64.0 20 59a —
“Ipsilateral Intra-pulmonary nodules” (IASLC T4) 46.2 11 47a 11a
T4-“invasion” (IASLC T4) 47.4 12 40b 10b
“Contralateral intra-pulmonary nodules” (IASLC M1a) 31.1 7 31b 6b
“Pleural dissemination” (IASLC M1a) 22.7 5 21b 4b
“Distant Metastasis” (IASLC M1b) 18.3 4 15b 3b
a Data from Groome PA, Bolejack V, Crowley JJ, et al. The IASLC lung cancer staging project: validation of the proposals for revision of the T, N, and M descriptors and
consequent stage grouping in the forth coming (seventh) edition of the TNM classification for lung cancer. J Thorac Oncol 2007;2:694–705.
b Data from Postmus PE, Brambilla E, Chansky K, et al. The IASLC lung cancer staging project: proposals for revision of the M descriptors in the forthcoming (seventh) edition
of the TNM classification of lung cancer. J Thorac Oncol 2007;2:686–693.
TABLE 5. Overall Survival of non-BAC NSCLC Patients with “IASLC T4”, Pleural Dissemination and Pericardial Effusion
without Distant Metastasis According to Nodal Status
Nodal Status Total Deaths
1-yr Survival
Estimate (%)
5-yr Survival
Estimate (%)
Median OS
(mo) p
“T4-invasion” (IASLC proposed T4) (N  1301)
N0 362 246 54.3 14.8 14 0.0001
N1 126 88 58.8 11.3 16
N2 707 539 43.6 9.8 11
N3 106 88 36.5 6.1 9
Malignant pleural dissemination (IASLC proposed M1a) (N  1773)
N0 480 398 32.1 6.2 6 0.0001
N1 73 63 31.6 7.4 6
N2 1050 945 18.3 2.4 4
N3 170 151 20.0 4.9 5
Malignant pericardial effusion (IASLC proposed M1a) (N  320)
N0 33 26 32.5 7.0 5 0.0461
N1 7 5 28.6 —a 7
N2 206 187 13.8 2.1 3
N3 74 64 21.8 4.0 5
a Data suppressed due to insufficient events after 10 mo.
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sion of stage IV into stage IVA and stage IVB is proposed
and adopted.
OS of Stage IA, IB, IIA, IIB, IIIA, IIIB, and IV
Patients According to Current (UICC6) and
Proposed IASLC Stage Grouping
The reclassification of all the patients in the study
(23,583) from the UICC6 stage grouping to IASLC stage
grouping were shown in Table 7. The 1-year and 5-year
survival estimates and median OS of UICC6 and IASLC
staging grouping for stages IA, IB, IIA, IIB, IIIA, IIIB, and
IV are listed in Table 8. The survival curves based on the
UICC6 and IASLC stage groupings are presented in Figures
3A, B, respectively. Similarly to the IASLC staging project
findings, there was overlap in OS between stage IB and IIA
patients in the UICC6 staging system. Survival comparison of
advanced staged NSCLC between the CCR validation set and
the IASLC SEER validation set is shown in Table 9.
External Multivariate Survival Analysis
Validation
Pairwise comparison of the HRs between each stage in
the UICC6 and IASLC were performed and the HRs, 95%
confidence interval (CI) and p value were listed in Table 10.
The HRs of the various stages of UICC6 and IASLC pro-
posed staging with stage IA as a referent were determined
with Cox proportional hazards analyses after adjusting for
multiple independent prognostic factors including age at
diagnosis, gender, ethnicity, socioeconomic status, histology,
tumor histologic grade, surgery, radiation, and chemotherapy.
The HRs, 95% CI and p-values of various stages of non-BAC
NSCLC as compared with stage I from both UICC6 and
IASLC stage are presented in Table 11. The complete list of
the HRs, 95% CI and p-values of the various prognostic
factors from the Cox proportional analyses were listed in
supplemental Table 1 (UICC6) and Table 2 (IASLC).
DISCUSSION
The current IASLC proposed changes to the TNM
descriptors and stage grouping represents a major and signif-
icant change to the staging of lung cancer.20 The original
external validation of these changes was performed using
data from SEER between 1998 and 2000.8 In this report, we
FIGURE 2. A, Overall survival curves of “T4-invasion” ac-
cording to nodal status. B, Overall survival curves of “pleural
dissemination” according to nodal status. C, Overall survival
curves of “pericardial effusion” according to nodal status.
TABLE 6. Pairwise Comparison of Hazards Ratio (HR) of
Death between Pericardial Effusion and Other IASLC M
Descriptors
Pairwise Comparison HR
95% Confidence
Interval p
Malignant pericardial effusion
vs. contralateral intra-
pulmonary nodules
1.453 1.271–1.660 0.0001
Malignant pericardial effusion
vs. malignant pleural
dissemination
1.146 1.010–1.302 0.0379
Malignant pericardial effusion
vs. distant metastasis (IASLC
M1b)
1.032 0.916–1.163 0.6090
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adopted all the proposed changes to the T4 and M descriptors
and reclassified advanced non-BAC NSCLC according to the
new stage grouping and performed a similar validation study
using data from the CCR during 1999–2003. We further
adopted all the proposed changes to the early T descriptors so
as to reclassify the stage all non-BAC NSCLC patients for the
Cox proportional hazards regression analysis.
The CCR is the largest contiguous-area population-
based cancer registry in the world, collecting over 130,000 of
new cancer cases per year in the state of California.19 Cali-
fornia legally mandated cancer reporting in 1988, and stan-
dardized data collection procedures and quality control pro-
cedures have been in place ever since.16 Case reporting is
estimated at98% of the entire state of California,21 and due
to data completeness, accuracy, and timeliness, CCR has
received the highest level of certification from the North
American Association of Central Cancer Registries.22 All the
regional cancer registries in California (Greater California)
became part of SEER in 2001. Before 2001, the San Fran-
cisco-Oakland regional registry was one of the nine original
SEER registries which started in 1973, whereas the San
Jose-Monterey and the Los Angeles regional registries be-
came part of SEER in 1992. Thus, there is some overlap and
some unique features of using CCR for this validation study
when compared with SEER validation set. CCR contains
additional data on socioeconomic status and chemotherapy
use during the first course of treatment, which are not re-
corded in SEER. Furthermore, California has an ethnically
diverse population with a total population of 35 million thus
allowing the inclusion of all major US ethnic groups to be
analyzed in the validation study. We have further excluded
10,934 NSCLC cases of cytologically diagnosed specimens
as cytology specimens have been shown to be inaccurate in
diagnosing NSCLC histology when compared with histolog-
ically diagnosed specimens,17 and 6932 nonmetastatic cases
where either the tumor (TX) or the nodal status is unknown
(NX). Finally our Cox proportional regression analysis in-
cluded other known prognostic factors such as histologic
grade,23,24 socioeconomic status,24,25 and treatment into the
analysis. The survival characteristics of the seven subtypes of
T4 and M descriptors from the CCR validation set and the
IASLC SEER validation set were very similar (Table 4).
Our current study on the stage-specific survival of
advanced non-BAC NSCLC using the CCR database essen-
tially agree with the improved prognostication of patients by
the IASLC proposed revisions to the T4 and M descriptors.
The changes are applicable to non-BAC NSCLC as a whole
and within adenocarcinoma, squamous cell carcinoma, large
cell carcinoma, or undifferentiated carcinomas. We have
performed a separated validation study of the IASLC staging
modifications for BAC using the CCR database,14 since we
had previously shown that the survival of BAC has improved
TABLE 7. Reclassifications of All Patients from the UICC6 Stage Grouping to IASLC Stage Grouping
UICC6 Stage
Grouping (total)
IASLC Stage Grouping (total)
IA (3000) IB (2573) IIA (1509) IIB (1037) IIIA (3660) IIIB (1677) IVA (3241)a IVB (6886)a
IA (3000) 3000 — — — — — — —
IB (3430) — 2573 608 249 — — — —
IIA (338) — — 338 — — — — —
IIB (1383) — — 563 607 213 — — —
IIIA (2531) — — — — 2460 71 — —
IIIB (4122) — — — 181 698 1150 2093 —
IV (8779) — — — — 289 456 1148 6886
TABLE 8. Comparison of Overall Survival between UICC6 Staging and IASLC Proposed Staging by Various Stages
UICC6 IASLC
Stage Total (%) Deaths
1-yr
Survival
Estimate
(%)
5-yr
Survival
Estimate
(%)
Median
Overall
Survival
(mo) Stage Total (%) Deaths
1-yr
Survival
Estimate
(%)
5-yr
Survival
Estimate
(%)
Median
Overall
Survival
(mo)
Stage IA 3000 (12.7%) 889 87.9 52.0 NR Stage IA 3000 (12.7%) 889 87.9 52.0 NR
Stage IB 3430 (14.5%) 1370 79.4 42.0 45 Stage IB 2573 (10.9%) 968 82.0 44.1 50
Stage IIA 338 (1.4%) 143 84.4 38.2 41 Stage IIA 1509 (6.4%) 718 76.1 32.6 35
Stage IIB 1383 (5.9%) 771 68.5 26.5 25 Stage IIB 1037 (4.4%) 556 68.4 29.3 25
Stage IIIA 2531 (10.7%) 1704 58.4 14.4 15 Stage IIIA 3660 (15.5%) 2424 58.8 15.9 16
Stage IIIB 4122 (17.5%) 3267 36.3 8.7 8 Stage IIIB 1677 (7.1%) 1305 41.4 8.1 10
Stage V 8779 (37.2%) 7756 22.4 2.4 5 Stage IVAa 3241 (13.7%) 2788 25.2 4.1 6
Stage IVBa 6886 (29.2%) 6252 18.3 1.3 4
a There is no official stage IVA (M1a) or stage IVB (M1b) as currently proposed by IASLC.
NR, not reached.
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significantly11 after the publication of the change WHO
definition change in BAC15 and that some of the proposed
changes to the T4 and M descriptors had a much more
pronounced survival effects in BAC, i.e., T4 due to additional
nodules and M due to ipsilateral pulmonary nodules.9,14
The current UICC6 T4 descriptor essentially encom-
passes three different tumor types: mediastinal invasion,
satellite nodules, and malignant pleural/pericardial dissemi-
nation. We believed IASLC had proposed revisions to the T4
descriptor that successfully separated these three categories.
T4 due to additional nodules will be reclassified as T3 in the
proposed IASLC revision. As shown in Table 2, the survival
of T4 patients due to additional nodules in the same lobe was
much better than the rest of the T4 and M descriptor group.
This observation is also valid among the individual NSCLC
histologies with adenocarcinoma having the best survival
time (Table 3). In separate analyses of the SEER database, we
have demonstrated that BAC patients with T4 due to addi-
tional nodules (T4N0M0) have a median OS of 46 months
and a 5-year survival estimate of 45%.9 Importantly, 72.0%
of the patients (T4N0M0) in that study underwent potential
curative lobectomy. Among non-BAC NSCLC patients in our
SEER analyses, 59% of the T4 (T4N0-2M0) patients with
additional nodules in the same lobe had surgical interven-
tion.10 This indicates that physicians treating NSCLC already
consider those T4 patients with additional nodules to have
better survival, and that most patients were treated with
curative intent. Bryant et al. reported the 5-year survival of 25
(T4-satellite nodules N0M0) patients who were staged by
positron emission tomography and underwent complete re-
section and neo-adjuvant or adjuvant chemotherapy was
57%.26 Thus reclassifying the T4 descriptor due to additional
nodules in the same lobe as T3 is clinically appropriate.20
Patients with pleural dissemination (malignant pleural
effusion/pleural nodules) in this report had extremely poor
survival. Similar to reported in the IASLC staging revision,4
we reported a 5-year survival rate of 3.1% and median
survival of 4 months in patients with pleural dissemination
but without distant metastasis in this study. We have also
shown that the poor survival of T4 due to pleural dissemina-
tion is essentially independent of mediastinal nodal status and
thus behaves more like distant metastasis (Table 5 and Figure
2B). These patients are considered as “wet IIIB” and treated
as stage IV in clinical practice and trials already. Thus
reclassifying T4 due to pleural dissemination as M1a codifies
what is being practiced in general.
Malignant pericardial effusion is currently staged as T4
in the UICC6 staging but will be reclassified as M1a with the
current proposed IASLC revision. The IASLC lung cancer
staging project did not separately analyze malignant pericar-
dial effusion from malignant pleural effusion within the
current T4 descriptor. In this report, we showed that isolated
pericardial effusion is much less common than isolated pleu-
ral dissemination in advanced lung cancer. We also showed
that median survival of patients with even isolated pericardial
effusion without distant metastasis was dismal with a median
survival time of 3 months and 5-year survival estimate of
3.4%. This dismal 3-month median survival time is consistent
FIGURE 3. A, Overall survival curves of individual stage ac-
cording to the UICC6 stage group. B, Overall survival curves
of individual stage according to the proposed IASLC stage
group.
TABLE 9. Comparison of Median Overall of Advanced
Stage non-BAC NSCLC between CCR Validation Set and
IASLC SEER Validation Set
Median Overall Survival (mo)
CCR
Validation Set
IASLC SEER
Validation Set
UICC6 IASLC UICC6 IASLC
Stage IIIA 15 16 14a 14a
Stage IIIB 8 10 8a 9a
Stage IV 5 — 4a 4a
Stage IVAb 6
Stage IVBb 4
a Data from Groome PA, Bolejack V, Crowley JJ, et al. The IASLC lung
cancer staging project: validation of the proposals for revision of the T, N,
and M descriptors and consequent stage grouping in the forth coming
(seventh) edition of the TNM classification for lung cancer. J Thorac Oncol
2007;2:694–705.
b There is no official stage IVA (M1a) and stage IVB (M1b) as proposed
by IASLC.
Ou and Zell Journal of Thoracic Oncology • Volume 3, Number 3, March 2008
Copyright © 2008 by the International Association for the Study of Lung Cancer224
with survival reported in other studies of patients with peri-
cardial effusion who underwent surgical pericardial window
for drainage.27,28 This poor survival is essentially independent
of mediastinal lymph node status (Table 5 and Figure 2C). In
fact, the survival of patients with pericardial effusion is closer
to M1b patients in our report than M1a patients. In pairwise
comparisons, the HR of patients with pericardial effusion was
significantly worse than patients with other M1a classifica-
tions such as contralateral intrapulmonary nodules or malig-
nant pleural dissemination but not statistically different from
patients with M1b disease (Table 6). Thus consideration
should be given to classify pericardial effusion as M1b rather
than M1a especially if there is going to be an official subdi-
vision of stage IV into stage IVA and stage IVB.
Similar to a previous analysis of the SEER database,10
in this report patients with M descriptor due to ipsilateral
intrapulmonary nodules had significantly better survival
among stage IV patients and similar survival to other “T4
invasion” patients (12 months median OS). This survival
advantage is again observed with each individual histology
(Table 3). Thus it is appropriate to reclassify M descriptor
due to ipsilateral pulmonary nodules as T4. In our previous
analysis using SEER database,9 BAC patients with ipsilateral
intrapulmonary nodules had a median survival of 20 months,
which is superior to the 15 months median survival observed
for adenocarcinoma in this report. Again a majority of the
BAC patients with ipsilateral pulmonary nodules (67.5%) in
our previous report underwent surgical treatment and those
patients had significantly prolonged survival.9 Nagai et al.
reported a 5-year survival of 42.1% in patients who under
surgical resection with intrapulmonary metastasis in different
lobes without mediastinal nodal metastasis.29 In this report,
31% of the M patients with ipsilateral intrapulmonary nod-
ules had surgical treatment (Table 1). Again these data
indicate that physicians are already treating a fair amount of
such patients with curative intent. Thus reclassifying patients
with ipsilateral pulmonary nodules from M to T4 makes
eminent clinical sense and is consistent with what is being
practiced in the community.
We adopted all the IASLC proposed T and M descrip-
tors changes and reclassified UICC6 stages IA, IB, IIA, IIB,
IIIA, IIIB, and IV into the new IASLC proposed stages IA,
IB, IIA, IIB, IIIA, IIIB, IVA, and IVB for the Cox propor-
tional hazards regression analysis. Similar to the IASLC stage
grouping analysis,7 there was no significant prognostic sig-
nificance between stage IB and IIA in the UICC6 clinical
staging system. The proposed IASLC stage grouping also
allows better separation of stage IB and IIA than UICC6
staging in our analysis (Tables 10 and 11). Furthermore, the
HRs for death continue to increase from stage IVA (versus
stage IA; HR  4.90) to stage IVB (versus stage IA; HR 
6.84) indicating that subdividing M descriptor into M1a and
M1b are justifiable even though the survival time for both
M1a and M1b patients are poor.30
TABLE 10. Pairwise Comparisons of Hazard Ratio of UICC and IASLC
Stages
Comparisons
Hazard Ratio p
UICC6 IASLC UICC6 IASLC
IB vs. IA 1.465 (1.347–1.594) 1.337 (1.221–1.465) 0.0001 0.0001
IIA vs. IB 0.996 (0.838–1.183) 1.369 (1.243–1.508) 0.9612 0.0001
IIB vs. IIA 1.639 (1.371–1.960) 1.267 (1.134–1.415) 0.0001 0.0001
IIIA vs. IIB 1.481 (1.360–1.613) 1.467 (1.338–1.609) 0.0001 0.0001
IIIB vs. IIIA 1.623 (1.530–1.721) 1.516 (1.417–1.622) 0.0001 0.0001
IV vs. IIIB 1.461 (1.403–1.523) 1.770 (1.669–1.876) 0.0001 0.0001
TABLE 11. Comparison of Hazards Ratio of Stage According to UICC6 and IASLC Proposed
Staging System Using Cox Proportional Hazards Regression Analysis
UICC6 IASLC
Stage
Hazards
Ratioa
95% Confidence
Interval p Stage
Hazards
Ratioa
95% Confidence
Interval p
Stage IA 1.00 Stage IA 1.00
Stage IB 1.414 (1.300–1.539) 0.0001 Stage IB 1.301 (1.188–1.426) 0.0001
Stage IIA 1.607 (1.347–1.918) 0.0001 Stage IIA 1.908 (1.729–2.107) 0.0001
Stage IIB 2.525 (2.291–2.784) 0.0001 Stage IIB 2.360 (2.120–2.626) 0.0001
Stage IIIA 2.798 (2.566–3.050) 0.0001 Stage IIIA 3.004 (2.767–3.261) 0.0001
Stage IIIB 3.686 (3.396–4.002) 0.0001 Stage IIIB 3.681 (3.346–4.048) 0.0001
Stage IV 5.246 (4.844–5.682) 0.0001 Stage IVAb 4.897 (4.493–5.338) 0.0001
Stage IVBb 6.842 (6.296–7.436) 0.0001
a Adjusted for age, gender, ethnicity, socioeconomic status, histology, histologic grade, surgery, radiation, and
chemotherapy. Refer to supplemental tables for the full Cox models.
b There is no official stage IVA (M1a) or stage IVB (M1b) as currently proposed by IASLC.
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One of the significant but potentially controversial
proposed IASLC stage grouping change is to down stage
T4N0-1M0 from the current UICC6 stage IIIB to stage IIIA.
Stage IIIA NSCLC is generally considered to be resectable
whereas stage IIIB is generally considered to be unresectable,
although there are exceptions to this conceptual categoriza-
tion. The 5-year survival estimate and median survival of the
IASLC proposed T4N0M0 (14.8% and 14 months) and
T4N1M0 (11.3% and 16 months) (Table 5) were closer to
UICC6 stage IIIA (14.4% and 15 months, Table 8) than
UICC stage IIIB (8.7% and 8 months, Table 8). A review of
published series on radical resection of T4 (trachea, carina,
left atrial, aortic, vena caval, or vertebral body invasion) lung
cancer with minimal nodal involvement reported a median
survival of 19 months and 5-year survival of 31%.31 Thus the
survival time analysis justifies moving T4N0-1M0 to stage
IIIA. Nonetheless, the current concept that stage IIIA NSCLC
represents resectable disease may be challenged in the future
if tumors that invade vertebral bodies, heart, pericardium,
major vessels with minimal mediastinal lymph node involve-
ment are staged as IIIA since the multidisciplinary surgical
skills required for radical resection of “T4 invasion” tumors
are not often available. Furthermore, practice guidelines will
have to be updated accordingly.32
This study is retrospective in nature and thus carried
with it limitations of population-based studies. There was no
uniform standard protocol on how the lung cancer patients
were staged (i.e., lymph node staging or systemic staging),
thus all the CCR registry patients were analyzed using “best
available stage” based on combined clinical and pathologic
staging data. A large number of cases were not analyzed due
to unknown histology, nodal status, or T-descriptor, thus
limiting our ability to generalize these findings to all non-
BAC NSCLC patients. There was no centralized review of
pathologic specimens. Nevertheless, the accuracy of NSCLC
histologic reporting in SEER has been reported favorably in
comparison to independent review.33 There is no uniform
protocol on how treatment (surgery, radiation, or chemother-
apy) was given. Despite these limitations, our pairwise com-
parison of survival characteristics of advanced NSCLC of our
CCR validation set is very similar to the IASLC SEER valida-
tion set. Moreover, we have included many independent prog-
nostic factors into the Cox proportional regression analysis.
In summary, the proposed staging changes reflect a
better prognostication of advanced stage IIIB and stage IV
NSCLC. Nevertheless, the survival of stage IIIB and stage IV
NSCLC regardless of current or proposed staging system
remains very poor. Future molecular tumor classifications,
lung cancer screening trial evaluations, and increased advo-
cacy of lung cancer research are critically needed.
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